{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-077715","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2022-07-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.264700+00:00","generated_at":"2026-06-24T20:53:43.353873+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Jaguar Health appoints Dr. Anula Jayasuriya to board, forms Business Development Advisory Committee","bullets":["Greg Divis resigned from Jaguar Health board effective July 1, 2022, after serving since 2018.","Dr. Anula Jayasuriya appointed as Class III director effective July 1, 2022; founder of EXXclaim Capital.","Board formed Business Development Advisory Committee chaired by Rachel Zolot Schwartz, VP at Volastra Therapeutics.","Dr. Jayasuriya receives $40,000 cash retainer and 128,851 restricted stock units under the 2014 Stock Incentive Plan.","Committee to identify and assess opportunities for potential alliances, mergers, and acquisitions for crofelemer asset."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-077715","json":"https://secwatch.observer/filing/0001104659-22-077715.json","markdown":"https://secwatch.observer/filing/0001104659-22-077715.md","text":"https://secwatch.observer/filing/0001104659-22-077715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000110465922077715/0001104659-22-077715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000110465922077715/tm2220394d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T20:53:43.353873+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1634d59ba1","claim":"Greg J. Divis resigned as Member of the Board at Jaguar Health, Inc..","evidence_excerpt":"Mr. Greg J. Divis notified the Board of Directors (the “Board”) of Jaguar Health, Inc. (the “Company”) of his intention to resign as a member of the Board, effective as of July 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465922077715/0001104659-22-077715-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of the Board"}],"fact_type":"executive_change"},{"claim_id":"6c6257fc74","claim":"Anula Jayasuriya was appointed as Class III Director at Jaguar Health, Inc..","evidence_excerpt":"the Board, by resolution as contemplated in the Company’s bylaws, appointed Dr. Anula Jayasuriya to fill the vacancy created by Mr. Divis’s resignation and serve as Class III director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465922077715/0001104659-22-077715-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}